Modality
ERT
MOA
WEE1i
Target
CD19
Pathway
Lipid Met
PBCSMAPSP
Development Pipeline
Preclinical
~Jun 2020
→ ~Sep 2021
Phase 1
Dec 2021
→ Aug 2028
Phase 1Current
NCT07660880
37 pts·PSP
2021-12→2028-08·Terminated
37 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-08-252.4y awayInterim· PSP
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Termina…
Catalysts
Interim
2028-08-25 · 2.4y away
PSP
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07660880 | Phase 1 | PSP | Terminated | 37 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| MDG-611 | Madrigal Pharma | Approved | CGRP | |
| Cevicapivasertib | Corcept | Phase 2 | CFTR |